![]() ![]() ![]() INTRODUCTION Recent escalating interest in the use of continuous glucose monitor (CGM) technology for hospitalized patients has been fueled by (1) improvements in the sensing and data management technology (2) increasing popularity of these devices among outpatients with diabetes as well as others from the athlete community and the quantified self movement (3) a recent surge of articles in leading diabetes journals describing both good accuracy and improved clinical outcomes in hospitalized patients using these devices (4) a recent decision by the United States Food and Drug Administration (FDA) related to the coronavirus disease 2019 (COVID-19) pandemic to exercise enforcement discretion and not block hospitals from providing devices and technical support to hospitals wishing to use these systems and (5) dissemination of guidelines and review articles describing policies for using CGMs in a hospital setting. Keywords: Blood glucose COVID-19 Diabetes mellitus Glucose Hospitals Intensive care units Technology.CGM technology is advancing and we expect that CGMs will be increasingly used in the hospital for patients with diabetes. Processes for collecting, reviewing, storing, and responding to CGM data must be established for such a program to be successful. ![]() A hospital CGM program requires cooperation of physicians, bedside nurses, diabetes educators, and hospital administrators to appropriately select and manage patients. Most of the research on CGMs in the hospital has focused on their accuracy and only recently outcomes data has been reported. CGMs can be used in the hospital to decrease the frequency of fingerstick point of care capillary blood glucose testing, decrease hyperglycemic episodes, and decrease hypoglycemic episodes. The United States Food and Drug Administration (FDA) is now exercising enforcement discretion and not objecting to certain factory-calibrated CGMs being used in a hospital setting, both to facilitate patient care and to obtain performance data that can be used for future regulatory submissions. The use of CGMs to automatically and remotely supplement or replace assisted monitoring of blood glucose by bedside nurses can decrease: the amount of necessary nursing exposure to COVID-19 patients with diabetes the amount of time required for obtaining blood glucose measurements, and the amount of personal protective equipment necessary for interacting with patients during the blood glucose testing. The coronavirus disease 2019 (COVID-19) pandemic has necessitated the use of new technologies and new processes to care for hospitalized patients, including diabetes patients. Continuous glucose monitors (CGMs) have suddenly become part of routine care in many hospitals. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |